Holen Sie sich die Stockscreener-App
499.74
1.77%
-9.01
Schlusskurs vom Vortag:
$508.75
Offen:
$511.06
24-Stunden-Volumen:
1.41M
Relative Volume:
1.05
Marktkapitalisierung:
$126.66B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
29.63
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
-2.03%
1M Leistung:
-2.63%
6M Leistung:
+14.71%
1J Leistung:
+22.30%
1-Tages-Spanne:
$497.49
$512.21
1-Wochen-Bereich:
$484.08
$517.68
52-Wochen-Spanne:
$403.16
$560.25
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-21 | Eingeleitet | Leerink Partners | Outperform |
| 2026-09-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2026-05-27 | Fortgesetzt | Truist | Buy |
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Meridian International Center Unveils Inaugural New Architects of American Influence Cohort - GlobeNewswire Inc.
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Zacks Investment Research
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders - The Motley Fool
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Zacks Investment Research
Is Vertex Stock Worth More Than Its Competitors? - Trefis
If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
RBC raises target for Vertex Pharma stock from USD 570 to USD 576 - AD HOC NEWS
RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating - www.marketscreener.com
Vertex to Announce Third Quarter 2026 Financial Results November 2nd - Business Wire
Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts - Yahoo Finance UK
Vertex Pharma stock after-hours at EUR 446.63: minus 0.62 percent versus prior close - AD HOC NEWS
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Healthcare Sector Highlights 16 A+ Growth Stocks Including Verte - GuruFocus
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets - Yahoo Finance
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy - BioSpace
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
Vertex Pharmaceuticals- Still Too Much Emphasis On CF SupremacyI Foresee A Downgrade - Seeking Alpha
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - The Motley Fool
UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating - Moomoo
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. - Yahoo Finance
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? - Yahoo Finance
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance
Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - fortune.com
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vertex Pharmaceuticals Inc-Aktie (VRTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. |
Jul 02 '26 |
Sale |
524.99 |
1,500 |
787,485 |
45,321 |
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Tatsis Ourania | Officer |
Jul 02 '26 |
Proposed Sale |
524.99 |
1,500 |
787,485 |
0 |
| McKechnie Duncan | Officer |
Jul 02 '26 |
Proposed Sale |
519.00 |
1,541 |
799,779 |
0 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
| Liu Joy | Officer |
Jul 01 '26 |
Proposed Sale |
502.71 |
828 |
416,244 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 26 '26 |
Sale |
482.50 |
596 |
287,570 |
15,337 |
| Bozic Carmen | Officer |
Jun 26 '26 |
Proposed Sale |
482.50 |
596 |
287,570 |
0 |
| Bozic Carmen | Officer |
Jun 18 '26 |
Proposed Sale |
462.17 |
1,020 |
471,413 |
0 |
| Bozic Carmen | EVP and CMO |
Jun 18 '26 |
Sale |
462.17 |
1,020 |
471,413 |
15,933 |
7.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):